Opioid withdrawal resident survival guide: Difference between revisions
Line 73: | Line 73: | ||
{{familytree | | | | | | C01 | | | | | | C02 | | | | | | | |C01=Short acting opioids|C02=Long acting opioids}} | {{familytree | | | | | | C01 | | | | | | C02 | | | | | | | |C01=Short acting opioids|C02=Long acting opioids}} | ||
{{familytree | | | | | | |!| | | | | | | |!| | | | | | | | |}} | {{familytree | | | | | | |!| | | | | | | |!| | | | | | | | |}} | ||
{{familytree | | | | | | D01 |-| D02 |-| D03 | | | | | | | | |D01=<div style="float: left; text-align: left">❑ Discontinue short acting opioids<br>❑ Look for withdrawal | {{familytree | | | | | | D01 |-| D02 |-| D03 | | | | | | | | |D01=<div style="float: left; text-align: left">❑ Discontinue short acting opioids<br>❑ Look for withdrawal symptoms (12-24 hours after last dose)</div>|D02=<div style="float: left; text-align: left">'''Withdrawal symptoms absent:'''<br>❑ Reevaluate the suitability for induction </div>|D03=<div style="float: left; text-align: left">❑ Taper down long acting opioids<br> | ||
:❑ Methadone to ≤30 mg/day | :❑ Methadone to ≤30 mg/day | ||
:❑ LAAM to ≤40 mg/48 hours<br> | :❑ LAAM to ≤40 mg/48 hours<br> | ||
❑ Look for withdrawal | ❑ Look for withdrawal symptoms:<br> | ||
:❑ For methadone: 24+ hours after last dose | :❑ For methadone: 24+ hours after last dose | ||
:❑ For LAAM: 48+ hours after last dose</div>}} | :❑ For LAAM: 48+ hours after last dose</div>}} | ||
{{familytree | | | | | | |!| | | | | | | |!| | | | | | | | | |}} | {{familytree | | | | | | |!| | | | | | | |!| | | | | | | | | |}} | ||
{{familytree | | | | | | E01 |-| E02 |-| E03 | | | | | | | | | |E01=<div style="float: left; text-align: left">'''Withdrawal | {{familytree | | | | | | E01 |-| E02 |-| E03 | | | | | | | | | |E01=<div style="float: left; text-align: left">'''Withdrawal symptoms present:'''<br>❑ Administer buprenorphine 4mg & Naloxone 1 mg<br>❑ Observe for 2+ hours</div>|E02=<div style="float: left; text-align: left">'''Withdrawal symptoms relieved:'''<br>❑ Day 1 dose established<BR>❑ Send home patient<BR>❑ Patient should return on day 2 for forward induction</div>|E03=<div style="float: left; text-align: left">'''Withdrawal symptoms present:'''<br>❑ Administer buprenorphine 2 mg<BR>❑ Observe 2+ hours</div>}} | ||
{{familytree | | | | | | |!| | | | | | | |!| | | | | | | | | |}} | {{familytree | | | | | | |!| | | | | | | |!| | | | | | | | | |}} | ||
{{familytree | | | | | | F01 | | | | | | F02 | | | | | | | | | |F01=<div style="float: left; text-align: left">'''Withdrawal | {{familytree | | | | | | F01 | | | | | | F02 | | | | | | | | | |F01=<div style="float: left; text-align: left">'''Withdrawal symptoms not relieved:'''<br>❑ Repeat<br> | ||
:❑ Buprenorphine 4mg (up to maximum of 8mg/24 hours) | :❑ Buprenorphine 4mg (up to maximum of 8mg/24 hours) | ||
:❑ Naloxone 1 mg (up to maximum of 2 mg/24 hours)</div>|F02=<div style="float: left; text-align: left">'''Withdrawal | :❑ Naloxone 1 mg (up to maximum of 2 mg/24 hours)</div>|F02=<div style="float: left; text-align: left">'''Withdrawal symptoms not relieved:'''<br>❑ Repeat<br> | ||
:❑ Buprenorphine 2mg (up to maximum of 8mg/24 hours)</div>}} | :❑ Buprenorphine 2mg (up to maximum of 8mg/24 hours)</div>}} | ||
{{familytree | | | | | | |`|-|-|-|v|-|-|-|'| | | | | | | | | |}} | {{familytree | | | | | | |`|-|-|-|v|-|-|-|'| | | | | | | | | |}} | ||
{{familytree | | | | | | |,|-|-|-|^|-|-|-|.| | | | | | | | | |}} | {{familytree | | | | | | |,|-|-|-|^|-|-|-|.| | | | | | | | | |}} | ||
{{familytree | | | | | | G01 | | | | | | G02 | | | | | | | | | |G01=<div style="float: left; text-align: left">'''Withdrawal | {{familytree | | | | | | G01 | | | | | | G02 | | | | | | | | | |G01=<div style="float: left; text-align: left">'''Withdrawal symptoms relieved:'''<br>❑ Day 1 dose established<BR>❑ Send home patient<BR>❑ Patient should return on day 2 for forward induction</div>|G02=<div style="float: left; text-align: left">'''Withdrawal symptoms not relieved:'''<br>Manage withdrawal symptoms symptomatically<br> | ||
:❑ [[Clonidine]] 0.2 mg every 4 hours, tapered after day 3,<ref name="O'Connor-1995">{{Cite journal | last1 = O'Connor | first1 = PG. | last2 = Waugh | first2 = ME. | last3 = Carroll | first3 = KM. | last4 = Rounsaville | first4 = BJ. | last5 = Diagkogiannis | first5 = IA. | last6 = Schottenfeld | first6 = RS. | title = Primary care-based ambulatory opioid detoxification: the results of a clinical trial. | journal = J Gen Intern Med | volume = 10 | issue = 5 | pages = 255-60 | month = May | year = 1995 | doi = | PMID = 7616334 }}</ref><br>'''or'''<br> | :❑ [[Clonidine]] 0.2 mg every 4 hours, tapered after day 3,<ref name="O'Connor-1995">{{Cite journal | last1 = O'Connor | first1 = PG. | last2 = Waugh | first2 = ME. | last3 = Carroll | first3 = KM. | last4 = Rounsaville | first4 = BJ. | last5 = Diagkogiannis | first5 = IA. | last6 = Schottenfeld | first6 = RS. | title = Primary care-based ambulatory opioid detoxification: the results of a clinical trial. | journal = J Gen Intern Med | volume = 10 | issue = 5 | pages = 255-60 | month = May | year = 1995 | doi = | PMID = 7616334 }}</ref><br>'''or'''<br> | ||
:❑ [[Lofexidine]] 0.2 mg BD daily, titrated to 1.2 mg BD daily <ref name="Strang-1999">{{Cite journal | last1 = Strang | first1 = J. | last2 = Bearn | first2 = J. | last3 = Gossop | first3 = M. | title = Lofexidine for opiate detoxification: review of recent randomised and open controlled trials. | journal = Am J Addict | volume = 8 | issue = 4 | pages = 337-48 | month = | year = 1999 | doi = | PMID = 10598217 }}</ref><br> | :❑ [[Lofexidine]] 0.2 mg BD daily, titrated to 1.2 mg BD daily <ref name="Strang-1999">{{Cite journal | last1 = Strang | first1 = J. | last2 = Bearn | first2 = J. | last3 = Gossop | first3 = M. | title = Lofexidine for opiate detoxification: review of recent randomised and open controlled trials. | journal = Am J Addict | volume = 8 | issue = 4 | pages = 337-48 | month = | year = 1999 | doi = | PMID = 10598217 }}</ref><br> | ||
Line 95: | Line 95: | ||
{{familytree | | | | | | |!| | | | | | | | | | | | | | | | | |}} | {{familytree | | | | | | |!| | | | | | | | | | | | | | | | | |}} | ||
{{familytree | | | | | | H01 | | | | | | | | | | | | | | | | | |H01='''Induction-day 2 forward'''}} | {{familytree | | | | | | H01 | | | | | | | | | | | | | | | | | |H01='''Induction-day 2 forward'''}} | ||
{{familytree | | | | | | |)|-|-|-|-|-|-| I01 | | | | | | | | |I01=<div style="float: left; text-align: left">'''On return withdrawal | {{familytree | | | | | | |)|-|-|-|-|-|-| I01 | | | | | | | | |I01=<div style="float: left; text-align: left">'''On return withdrawal symptoms absent:'''<br>❑ Administer a daily dose established equal to total buprenorphine & naloxone administered on previous day </div>}} | ||
{{familytree | | | | | | J01 | | | | | | | | | | | | | | | | | |J01=<div style="float: left; text-align: left">'''On return withdrawal | {{familytree | | | | | | J01 | | | | | | | | | | | | | | | | | |J01=<div style="float: left; text-align: left">'''On return withdrawal symptoms present:'''<br>❑ Administer dose equal to<br>Total amount of buprenorphine & naloxone administered on previous day<br>'''+'''<br>4mg of buprenorphine (up to maximum of 12mg on day 2)<br>&<br>1mg of naloxone (up to maximum of 3mg on day 2)<br>❑ Observe 2+ hours</div> }} | ||
{{familytree | | | | | | |)|-|-|-|-|-|-| K01 | | | | | | | | |K01=<div style="float: left; text-align: left">'''Withdrawal | {{familytree | | | | | | |)|-|-|-|-|-|-| K01 | | | | | | | | |K01=<div style="float: left; text-align: left">'''Withdrawal symptoms relieved:'''<br>❑ Daily buprenorphine & naloxone dose established </div>}} | ||
{{familytree | | | | | | L01 | | | | | | | | | | | | | | | | | |L01=<div style="float: left; text-align: left">'''Withdrawal | {{familytree | | | | | | L01 | | | | | | | | | | | | | | | | | |L01=<div style="float: left; text-align: left">'''Withdrawal symptoms not relieved:'''<br>❑ Administer buprenorphine 4 mg (up to maximum of 16mg on day 2) & naloxone 1 mg (up to maximum of 4 mg on day 2)</div> }} | ||
{{familytree | | | | | | |)|-|-|-|-|-|-| M01 | | | | | | | | |M01=<div style="float: left; text-align: left">'''Withdrawal | {{familytree | | | | | | |)|-|-|-|-|-|-| M01 | | | | | | | | |M01=<div style="float: left; text-align: left">'''Withdrawal symptoms relieved:'''<br>❑ Daily buprenorphine & naloxone dose established </div>}} | ||
{{familytree | | | | | | N01 | | | | | | | | | | | | | | | | | |N01=<div style="float: left; text-align: left">'''Withdrawal | {{familytree | | | | | | N01 | | | | | | | | | | | | | | | | | |N01=<div style="float: left; text-align: left">'''Withdrawal symptoms not relieved:'''<br>Manage withdrawal symptoms symptomatically<br> | ||
:❑ [[Clonidine]] 0.2 mg every 4 hours, tapered after day 3,<ref name="O'Connor-1995">{{Cite journal | last1 = O'Connor | first1 = PG. | last2 = Waugh | first2 = ME. | last3 = Carroll | first3 = KM. | last4 = Rounsaville | first4 = BJ. | last5 = Diagkogiannis | first5 = IA. | last6 = Schottenfeld | first6 = RS. | title = Primary care-based ambulatory opioid detoxification: the results of a clinical trial. | journal = J Gen Intern Med | volume = 10 | issue = 5 | pages = 255-60 | month = May | year = 1995 | doi = | PMID = 7616334 }}</ref><br>'''or'''<br> | :❑ [[Clonidine]] 0.2 mg every 4 hours, tapered after day 3,<ref name="O'Connor-1995">{{Cite journal | last1 = O'Connor | first1 = PG. | last2 = Waugh | first2 = ME. | last3 = Carroll | first3 = KM. | last4 = Rounsaville | first4 = BJ. | last5 = Diagkogiannis | first5 = IA. | last6 = Schottenfeld | first6 = RS. | title = Primary care-based ambulatory opioid detoxification: the results of a clinical trial. | journal = J Gen Intern Med | volume = 10 | issue = 5 | pages = 255-60 | month = May | year = 1995 | doi = | PMID = 7616334 }}</ref><br>'''or'''<br> | ||
:❑ [[Lofexidine]] 0.2 mg BD daily, titrated to 1.2 mg BD daily <ref name="Strang-1999">{{Cite journal | last1 = Strang | first1 = J. | last2 = Bearn | first2 = J. | last3 = Gossop | first3 = M. | title = Lofexidine for opiate detoxification: review of recent randomised and open controlled trials. | journal = Am J Addict | volume = 8 | issue = 4 | pages = 337-48 | month = | year = 1999 | doi = | PMID = 10598217 }}</ref><br> | :❑ [[Lofexidine]] 0.2 mg BD daily, titrated to 1.2 mg BD daily <ref name="Strang-1999">{{Cite journal | last1 = Strang | first1 = J. | last2 = Bearn | first2 = J. | last3 = Gossop | first3 = M. | title = Lofexidine for opiate detoxification: review of recent randomised and open controlled trials. | journal = Am J Addict | volume = 8 | issue = 4 | pages = 337-48 | month = | year = 1999 | doi = | PMID = 10598217 }}</ref><br> | ||
Line 107: | Line 107: | ||
{{familytree | | | | | | |!| | | | | | | | | | | | | | | | }} | {{familytree | | | | | | |!| | | | | | | | | | | | | | | | }} | ||
{{familytree | | | | | | O01 | | | | | | | | | | | | | | |O01=<div style="float: left; text-align: left">Stabilization phase (1-2 months): <br> ❑ Transition when patient has: | {{familytree | | | | | | O01 | | | | | | | | | | | | | | |O01=<div style="float: left; text-align: left">Stabilization phase (1-2 months): <br> ❑ Transition when patient has: | ||
: | :❑ No withdrawal symptoms <br> | ||
: | :❑ Minimal or no side effects <br> | ||
: | :❑ No uncontrollable craving for opioid agonists <br> | ||
❑ Begin with buprenorphine/naloxone combination, increasing dose by 2/0.5-4/1 mg per week till stabilization is achieved, most stabilizing at 16/4-24/6 mg <br> ❑ As patient stabilizes, transition to alternate day or every third day regimen by doubling and tripling daily doses respectively </div> }} | ❑ Begin with buprenorphine/naloxone combination, increasing dose by 2/0.5-4/1 mg per week till stabilization is achieved, most stabilizing at 16/4-24/6 mg <br> ❑ As patient stabilizes, transition to alternate day or every third day regimen by doubling and tripling daily doses respectively </div> }} | ||
{{familytree | | | | | | |!| | | | | | | | | | | }} | {{familytree | | | | | | |!| | | | | | | | | | | }} | ||
{{familytree | | | | | | P01 | | | | | | | | | |P01=<div style="float: left; text-align: left">Maintenance phase: <br> | {{familytree | | | | | | P01 | | | | | | | | | |P01=<div style="float: left; text-align: left">Maintenance phase: <br> | ||
❑ Maintain at same dose as daily stabilization dose <br> ❑ Decide total treatment duration based on: <br> | ❑ Maintain at same dose as daily stabilization dose <br> ❑ Decide total treatment duration based on: <br> | ||
: | :❑ Stable housing & income <br> | ||
: | :❑ Patients motivation, doctors comfort in tapering <br> | ||
: | :❑ Presence of psychosocial support | ||
: | :❑ Absence of legal support | ||
: | :❑ Other drugs & alcohol abuse </div> }} | ||
{{familytree/end}} | {{familytree/end}} | ||
Revision as of 02:11, 7 February 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Vidit Bhargava, M.B.B.S [2]; Vendhan Ramanujam M.B.B.S [3]
Definition
Opioid withdrawal refers to the arrays of signs and symptoms following the abrupt cessation of opioids among chronic users.
Shown below is a table indicative of time to withdrawal symptoms for different opioids:[1][2]
Opioid | Peak withdrawal symptoms | Duration of symptoms |
---|---|---|
Heroin | 36-72 hours | 7-10 days |
Methadone | 72-96 hours | 14 days or more |
Buprenorphine | 36-72 hours | Intermediate between 7-14 days |
Causes
Life Threatening Causes
Life-threatening causes include conditions which may result in death or permanent disability within 24 hours if left untreated. Opioid withdrawal is a life-threatening condition and must be treated as such irrespective of the causes.
Common Causes
- Discontinuation of heroin
- Discontinuation of methadone
- Rapid detoxification with naloxone or naltrexone in opioid dependent subjects
- Use of partial agonists (buprenorphine) and/or agonist-antagonists (pentazocine) in subjects not known to be opioid dependent
Management
Diagnostic Approach
Shown below is an algorithm depicting the management of opioid withdrawal.[3]
Characterize the symptoms: ❑ Flu like illness ❑ Lacrimation ❑ Rhinorrhea ❑ Sneezing ❑ Yawning ❑ Anorexia ❑ Nausea ❑ Vomiting ❑ Abdominal cramps ❑ Diarrhea ❑ Myalgia ❑ Arthralgia | |||||||||||||||||||||||||||||
Examine the patient: ❑ Increased or unchanged blood pressure ❑ Increased or unchanged heart rate ❑ Increased or unchanged respiratory rate ❑ Mydriasis ❑ Piloerection ❑ Tremor ❑ Increased bowel sounds | |||||||||||||||||||||||||||||
Consider alternative diagnosis: ❑ Alcohol withdrawal ❑ Sedative hypnotic withdrawal ❑ Cholinergic poisoning ❑ Sympathomimetic intoxication | |||||||||||||||||||||||||||||
Diagnostic criteria: ❑ A. Either of the following
❑ B. Three or more of the following (developing within minutes to several days after criterion A)
| |||||||||||||||||||||||||||||
Consider treatment with: ❑ Opioid maintenance treatment or ❑ Medically supervised withdrawal (detoxification) | |||||||||||||||||||||||||||||
Treatment Approach
Opioid Maintenance Treatment
Induction-day 1 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Identify the opioid(s) that the patient has been using | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short acting opioids | Long acting opioids | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
❑ Discontinue short acting opioids ❑ Look for withdrawal symptoms (12-24 hours after last dose) | Withdrawal symptoms absent: ❑ Reevaluate the suitability for induction | ❑ Taper down long acting opioids
❑ Look for withdrawal symptoms:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Withdrawal symptoms present: ❑ Administer buprenorphine 4mg & Naloxone 1 mg ❑ Observe for 2+ hours | Withdrawal symptoms relieved: ❑ Day 1 dose established ❑ Send home patient ❑ Patient should return on day 2 for forward induction | Withdrawal symptoms present: ❑ Administer buprenorphine 2 mg ❑ Observe 2+ hours | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Withdrawal symptoms not relieved: ❑ Repeat
| Withdrawal symptoms not relieved: ❑ Repeat | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Withdrawal symptoms relieved: ❑ Day 1 dose established ❑ Send home patient ❑ Patient should return on day 2 for forward induction | Withdrawal symptoms not relieved: Manage withdrawal symptoms symptomatically
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Induction-day 2 forward | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
On return withdrawal symptoms absent: ❑ Administer a daily dose established equal to total buprenorphine & naloxone administered on previous day | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
On return withdrawal symptoms present: ❑ Administer dose equal to Total amount of buprenorphine & naloxone administered on previous day + 4mg of buprenorphine (up to maximum of 12mg on day 2) & 1mg of naloxone (up to maximum of 3mg on day 2) ❑ Observe 2+ hours | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Withdrawal symptoms relieved: ❑ Daily buprenorphine & naloxone dose established | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Withdrawal symptoms not relieved: ❑ Administer buprenorphine 4 mg (up to maximum of 16mg on day 2) & naloxone 1 mg (up to maximum of 4 mg on day 2) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Withdrawal symptoms relieved: ❑ Daily buprenorphine & naloxone dose established | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Withdrawal symptoms not relieved: Manage withdrawal symptoms symptomatically
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stabilization phase (1-2 months): ❑ Transition when patient has:
❑ As patient stabilizes, transition to alternate day or every third day regimen by doubling and tripling daily doses respectively | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Maintenance phase: ❑ Maintain at same dose as daily stabilization dose
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Detoxification (Medically Supervised Withdrawal) With Buprenorphine
Do's
- Treat the patient for a duration of 10 days for heroin withdrawal and 14 days for methadone withdrawal.
- Restrict methadone and other opioid agonists to inpatient settings or licensed programs.
- Administer chlordiazepoxide, a longer-acting benzodiazepine to augment clonidine in patients with insomnia or muscle cramps.[4]
- Detoxification should be undertaken only under clinicians with special training, equipment, or both.
- Start buprenorphine at least two days before starting naltrexone during detoxification.
Dont's
- Do not abruptly stop drugs that are being used to treat withdrawal.
References
- ↑ Jasinski, DR.; Pevnick, JS.; Griffith, JD. (1978). "Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction". Arch Gen Psychiatry. 35 (4): 501–16. PMID 215096. Unknown parameter
|month=
ignored (help) - ↑ Opiods: detoxification. In: Galanter M, Kleber HD, eds. The American Psychiatric Press textbook of substance abuse treatment. 2nd ed. Washington, D.C.: American Psychiatric Press, 1999:251-69.>
- ↑ Huitink, J.; Buitelaar, D. (2003). "Management of drug and alcohol withdrawal". N Engl J Med. 349 (4): 405–7, author reply 405-7. PMID 12879900. Unknown parameter
|month=
ignored (help) - ↑ 4.0 4.1 4.2 O'Connor, PG.; Waugh, ME.; Carroll, KM.; Rounsaville, BJ.; Diagkogiannis, IA.; Schottenfeld, RS. (1995). "Primary care-based ambulatory opioid detoxification: the results of a clinical trial". J Gen Intern Med. 10 (5): 255–60. PMID 7616334. Unknown parameter
|month=
ignored (help) - ↑ 5.0 5.1 Strang, J.; Bearn, J.; Gossop, M. (1999). "Lofexidine for opiate detoxification: review of recent randomised and open controlled trials". Am J Addict. 8 (4): 337–48. PMID 10598217.